Kalincik, T. Et Al. 2017. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. LANCET NEUROLOGY , vol.16, no.4 , 271-281.

Kalincik, T., Brown, J. W. L., Robertson, N., Willis, M., Scolding, N., Rice, C. M., ... Wilkins, A.(2017). Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. LANCET NEUROLOGY , vol.16, no.4, 271-281.

Kalincik, Tomas Et Al. "Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study," LANCET NEUROLOGY , vol.16, no.4, 271-281, 2017

Kalincik, Tomas Et Al. "Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study." LANCET NEUROLOGY , vol.16, no.4, pp.271-281, 2017

Kalincik, T. Et Al. (2017) . "Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study." LANCET NEUROLOGY , vol.16, no.4, pp.271-281.

@article{article, author={Tomas Kalincik Et Al. }, title={Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study}, journal={LANCET NEUROLOGY}, year=2017, pages={271-281} }